Supplementary Figure S4 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Supplementary Figure S4. Full patient disposition for the Phase I/Ib substudies. A, CEA-IL2v monotherapy with or without obinutuzumab pretreatment. The red boxes indicate the data used to support the information included within the manuscript. B, CEA-IL2v in combination with atezolizumab with or without obinutuzumab pretreatment. The red boxes indicate the data used to support the information included within the manuscript.